One Stop Solution For In-Depth Market Research Reports

詳細な市場調査レポートのワンストップソリューション

Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Drug Discovery Outsourcing (DDO) Global Market

創薬アウトソーシング(DDO)市場ー業界洞察、主要プレーヤー・企業別、成長機会別、最新傾向別、開発別、主要な成長ドライバー別、主要な課題別によってセグメンテーション、予測 2028年


[ 英語タイトル ] Drug Discovery Outsourcing (DDO) Global Market – Forecast To 2030


Product Code : IQ4IHC00114187
Survey : IQ4I
Publish On : July, 2021
Number of Pages : 238
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD7200 / Question Form
5 User USD9000 / Question Form
Enterprise User USD12000 / Question Form
AMRI
ARAGEN LIFESCIENCES (GVK BIOSCIENCES)
AURIGENE DISCOVERY
BIODURO-SUNDIA
CHARLES RIVER LABORATORIES (CRL)
CHEMPARTNER
EUROFINS
EVOTEC
JUBILANT BIOSYS
PHARMARON INC.
SAI LIFESCIENCES
SHANGHAI MEDICILON
SYNGENE
SELVITA SA
SYGNATURE DISCOVERY
TCG LIFESCIENCES
VIVA BIOTECH
WUXIAPPTEC
WUXI BIOLOGICS

[Report Description]

Over the last two decades, the Pharmaceutical industry has seen a radical change. The unprecedented downsizing of the internal discovery of big pharmaceuticals, patent expiration, shift towards biologics have seen a surge in the externalization and outsourcing activities. As the industry is looking for new sources of discovery and innovation with limited resources, there is a growing preference to move towards externalization and willingness to embrace the concept of outsourcing.
Around 25 - 35% of the global pharmaceutical companies R&D spending goes into drug discovery outsourcing. Almost all the major Pharmaceutical companies are considering outsourcing as a core strategy to fill their discovery pipelines. Contract Research Organisation (CRO) that have precise capabilities through greater flexibility are the preferred ones. Now–a–days, the big pharma relies more on CRO’s for drug discovery capabilities to stock up their pipelines.
The global pharmaceutical outsourcing market (Discovery, Preclinical & Clinical Services) is estimated to be $50 - 70 billion in 2020, which accounts to 25 - 40% of the overall pharma R&D spending. Out of $50 - 70 billion, 30 - 40% accounts for discovery-based service i.e. $20 - 30 billion in 2020. Pre clinical and Clinical related services accounts to 10 - 20% and 40 - 60% respectively.
This report provides comprehensive insights on the global drug discovery outsourcing market. The report covers all segments, global trends and emerging strategies of the outsourcing market related to drug discovery. Major Drug Discovery Outsourcing (DDO) players included in the report are AMRI, Aragen Lifesciences (GVK Bio), Aurigene Discovery, Bioduro-Sundia, Charles River Laboratories (CRL), ChemPartner, Eurofins, Evotec, Jubilant Biosys, Pharmaron, Sai Lifesciences, Shanghai Medicilon, Syngene, Selvita S.A., Sygnature Discovery, TCG Lifesciences, VIVA Biotech, WuxiApptec and Wuxi Biologics.
This report caters to the need of Contract research organizations, Pharmaceutical/Biotech companies, Academic institutes, Individual researchers, Investors, Service providers and other associated stake holders to identify and analyze the potential of the DDO market. The report also provides insights on customer base, number of deals between CRO’s and Pharmaceutical /biotech firms, global FTE rates, employee strength & number of companies, revenue per employee of major players, therapeutic area gap analysis and successful research collaboration outcomes of selected CRO’s and Sponsors, which are likely to have an impact on the DDO market in the foreseeable future.
This report covers in-depth analysis of major players by therapeutic area of focus, capabilities, geographic presence, business models, financials, collaborations, acquisitions, various marketing strategies adopted along with insightful analysis on conferences, clusters and match making websites.

1 INTRODUCTION
2 MARKET ANALYSIS
2.1 RESEARCH METHODOLOGY
2.2 FORECASTING MODEL
2.3 MARKET DYNAMICS
2.4 MARKET SIZING
2.5 TRENDS & STRATEGIES IN THE CRO INDUSTRY
2.6 IMPACT OF COVID-19 ON THE CRO INDUSTRY
3 BUSINESS OVERVIEW
3.1 BUSINESS MODELS
3.2 BUSINESS EVOLUTION
3.3 CERTIFICATIONS
3.4 DD INDICATORS
3.5 PHARMACEUTICAL R&D EXP & INTENSITY
3.6 PHARMACEUTICAL THERAPEUTIC AREA ANALYSIS
3.7 SELECTED PHARMACEUTICAL PLAYERS-AREA OF INTEREST
4 COMPETITOR ANALYSIS
4.1 THERAPEUTIC AREA MATRIX
4.2 GLOBAL FTE RATES
4.3 REGIONAL REVENUES VS FTE
4.4 CUSTOMER BASE
4.5 DEALS
4.6 THERAPEUTIC AREA ANALYSIS
4.7 THERAPEUTIC AREA GAP ANALYSIS
4.8 SELECTED CRO TRACK RECORD OF SUCCESS & DISTINGUISHED CORE CAPABILITIES
4.9 START-UP CROs & THEIR DIFFERENTIATED AREA OF EXPERTISE
4.10 PRICING ANALYSIS OF VARIOUS DRUG DISCOVERY SERVICES
4.11 SUCCESSFUL COLLABORATIONS
5 LEADING PLAYERS
5.1 OVERVIEW
5.2 CAPABILITIES
5.3 THERAPEUTIC AREA
5.4 BUSINESS MODELS
5.5 COLLABORATIONS
5.6 ACQUISITIONS
6 MARKETING STRATEGIES
6.1 CONFERENCES
6.1.1 CONFERENCES -2018, 2019, 2020, 2021
6.1.2 CONFERENCE ANALYSIS- 2018, 2019, 2020
6.2 MATCH MAKING WEBSITES
6.3 VIRTUAL PHARMACEUTICALS
6.4 ONLINE RPFS
6.5 NETWORKING WEBSITES
6.6 CLUSTERS
6.7 OTHER MARKETING STRATEGIES
6.7.1 WEBSITE RANKINGS
6.8 REFERENCES

渋谷データカウント

渋谷データカウントは、最も信頼性が高く最新の調査分析レポートを確実に提供する経験豊富な調査専門家のグローバルチームが提供する、さまざまな業界のさまざまな市場調査レポートを提供する再販代理店です。

Recommended reports

+